2.64
price down icon3.65%   -0.10
after-market Handel nachbörslich: 2.66 0.02 +0.76%
loading

Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten

pulisher
May 31, 2025

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN

May 30, 2025
pulisher
May 30, 2025

Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com

May 30, 2025
pulisher
May 30, 2025

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN

May 30, 2025
pulisher
May 29, 2025

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter

May 29, 2025
pulisher
May 28, 2025

Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News

May 28, 2025
pulisher
May 28, 2025

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga

May 28, 2025
pulisher
May 28, 2025

GSK, Spero stop UTI drug trial after early success - Reuters

May 28, 2025
pulisher
May 28, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com Nigeria

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance

May 28, 2025
pulisher
May 17, 2025

Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World

May 17, 2025
pulisher
May 15, 2025

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Spero Therapeutics Advances Phase 3 Trial With Strong Cash Position, Welcomes New CEO - Stock Titan

May 13, 2025
pulisher
May 13, 2025

SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus

May 13, 2025
pulisher
May 07, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World

May 07, 2025
pulisher
May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times

May 05, 2025
pulisher
May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune

May 05, 2025
pulisher
Apr 30, 2025

Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 30, 2025
pulisher
Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz

Apr 28, 2025
pulisher
Apr 28, 2025

New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Spero Therapeutics appoints new CEO and board nominee - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Spero Therapeutics appoints new CEO and board nominee By Investing.com - Investing.com Canada

Apr 28, 2025
pulisher
Apr 26, 2025

Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 12, 2025
pulisher
Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 07, 2025

Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire

Apr 07, 2025
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price down icon 0.60%
Kapitalisierung:     |  Volumen (24h):